Cleveland, Ohio 44195


RATIONALE: Specialized radiation therapy that delivers radiation directly to the area where a tumor was surgically removed may kill any remaining tumor cells and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying radiation therapy to see how well it works in treating patients who are undergoing surgery to remove a metastatic brain tumor.

Study summary:

OBJECTIVES: Primary - Determine the 1-year local control rate in patients undergoing resection of a solitary brain metastasis comprising intraoperative radiotherapy using the INTRABEAM® system. Secondary - Determine the survival of patients treated with this therapy. - Determine distant recurrence of disease in patients treated with this therapy. - Determine the toxicity of this therapy in these patients. - Determine the quality of life of patients treated with this therapy. OUTLINE: This is a nonrandomized study. Patients undergo surgical resection of a brain metastasis. Patients then undergo intraoperative radiotherapy using the INTRABEAM® system. Quality of life is assessed at baseline and then every 3 months for 2 years. Patients are followed within 48 hours after surgery, at 1 and 3 months, and then every 3 months for 2 years. PROJECTED ACCRUAL: A total of 31-62 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Newly diagnosed supratentorial solitary brain metastasis by enhanced MRI or CT scan - Resectable disease - Histological evidence of metastatic carcinoma by intraoperative pathology - No primary lymphoma, germ cell carcinoma, or small cell lung cancer PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 70-100% Life expectancy - At least 3 months Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified Cardiovascular - No uncontrolled hypertension - No unstable angina pectoris - No uncontrolled dysrhythmias Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No serious infection - No other medical illness that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior temozolomide or polifeprosan 20 with carmustine implant (Gliadel® wafer) for brain metastasis Endocrine therapy - Not specified Radiotherapy - No prior brain radiotherapy of any kind, including local or whole brain external beam radiotherapy, brachytherapy, or stereotactic radiosurgery - No concurrent external beam radiotherapy to the brain - Not planning adjuvant whole brain radiotherapy after study therapy Surgery - Not specified Other - No other prior conventional or investigational local or systemic agents for brain metastasis



Primary Contact:

Study Chair
Robert Weil, MD
The Cleveland Clinic

Backup Contact:


Location Contact:

Cleveland, Ohio 44195
United States

Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente
Phone: 866-223-8100

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.